A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

Abstract

This interventional study provides class 1 evidence that dalfampridine extended-release tablets produce clinically meaningful improvement in walking ability in a subset of people with MS, with the effect maintained between doses.